New findings have the potential to significantly benefit the field of neuroscience and could help guide researchers in designing more cost-effective, fruitful studies of the brain. 

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.

A heart team chose to perform BASILICA before valve-in-valve TAVR in a failed Lotus device to help minimize the risk of complications. These scenarios will likely grow more and more common as patients outlive their TAVR valves.

Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others. 

ICAD shareholders filed suit against the transaction last month in New York, claiming financial estimates used in the deal are misleading. 

The Mobile Cancer Screening Act would offer grants to help imaging providers purchase mobile CT screening units through the federal government. 
 

Human Longevity is a luxury clinic that's part of a “lucrative and growing industry” focused on preventive care. 

The numbers from Pittsburgh are staggering. And they’re all about blasting American-made AI into the stratosphere, if not to Infinity and beyond. 

Over 97% of all counties in the U.S. see high or very high levels of consolidation in Medicare Advantage markets, with UnitedHealthcare and Humana owning the most plans nationwide.